Nexalin Technology (NXL) Return on Capital Employed (2022 - 2026)
Nexalin Technology (NXL) posted quarterly Return on Capital Employed of 253.22% for Q1 2026, up 3781.0% year-over-year from 6.52% in Q1 2025, and down 20.51% quarter-over-quarter from 210.12% in Q4 2025.
Nexalin Technology (NXL) Return on Capital Employed (2022 - 2026) Analysis & Trends
Nexalin Technology's Return on Capital Employed history runs 5 years deep, the most recent figure standing at 253.22% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 3781.0% year-over-year to 253.22%; the TTM figure through Mar 2026 stood at 253.22% (up 3781.0% YoY), while the FY2025 annual figure was 236.92%, down 753.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 253.22%, down from 210.12% in the prior quarter.
- The five-year high for Return on Capital Employed was 30.84% in Q4 2022, with the low at 322.71% in Q2 2024.
- The 5-year median for Return on Capital Employed is 197.0% (2024), against an average of 178.13%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed slumped 26163 bps in 2024, then jumped 10448 bps in 2025.
- Nexalin Technology's Return on Capital Employed stood at 30.84% in 2022, then plunged by 412 bps to 157.9% in 2023, then declined by 17 bps to 184.93% in 2024, then decreased by 14 bps to 210.12% in 2025, then dropped by 21 bps to 253.22% in 2026.
- Business Quant data shows NXL's Return on Capital Employed at 253.22% in Q1 2026, 210.12% in Q4 2025, and 161.33% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 7.98% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 13.69% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 8.02% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 10.83% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 11.99% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 27.21% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 9.47% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 12.84% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 12.08% |
| 10 | Nexalin Technology | 7.04 Mn | 6.03 Mn | 8,897.00 | -489.42% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -489.42% |
| Mar 31, 2026 | -253.22% |
| Dec 31, 2025 | -210.12% |
| Sep 30, 2025 | -161.33% |
| Jun 30, 2025 | -218.23% |
| Mar 31, 2025 | -291.03% |
| Dec 31, 2024 | -184.93% |
| Sep 30, 2024 | -209.07% |
| Jun 30, 2024 | -322.71% |
| Mar 31, 2024 | -219.77% |
| Dec 31, 2023 | -157.90% |
| Sep 30, 2023 | -132.81% |
| Jun 30, 2023 | -61.07% |
| Mar 31, 2023 | -40.78% |
| Dec 31, 2022 | -30.84% |